Aby J. Mathew Sells 25,000 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 25,000 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $21.17, for a total transaction of $529,250.00. Following the sale, the executive vice president now owns 302,046 shares of the company’s stock, valued at approximately $6,394,313.82. The trade was a 7.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

BioLife Solutions Trading Up 9.6 %

Shares of NASDAQ:BLFS traded up $1.97 on Tuesday, hitting $22.44. The company had a trading volume of 713,055 shares, compared to its average volume of 382,708. The firm’s 50-day simple moving average is $23.94 and its two-hundred day simple moving average is $22.84. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -21.05 and a beta of 1.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 1 year low of $11.91 and a 1 year high of $28.88.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BLFS shares. TD Cowen increased their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Craig Hallum boosted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright cut their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday. Finally, Northland Securities upped their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and an average target price of $27.50.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in BioLife Solutions by 11.5% during the first quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock worth $53,208,000 after acquiring an additional 296,727 shares in the last quarter. Fred Alger Management LLC boosted its position in shares of BioLife Solutions by 6.0% in the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after purchasing an additional 88,840 shares in the last quarter. State Street Corp boosted its position in shares of BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after buying an additional 18,473 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in BioLife Solutions by 9.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock valued at $17,034,000 after buying an additional 66,422 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.